Stern AS, Podlaski FJ, Hulmes JD et al (1990) Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells. Proc Natl Acad Sci USA 87:6808–6812
PubMed Central
PubMed
CAS
Google Scholar
Kobayashi M, Fitz L, Ryan M et al (1989) Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med 170:827–845
PubMed
CAS
Google Scholar
Jakobisiak M, Lasek W, Golab J (2003) Natural mechanisms protecting against cancer. Immunol Lett 90:103–122
PubMed
CAS
Google Scholar
Heufler C, Koch F, Stanzl U et al (1996) Interleukin-12 is produced by dendritic cells and mediates T helper 1 development as well as interferon-gamma production by T helper 1 cells. Eur J Immunol 26:659–668
PubMed
CAS
Google Scholar
Nizzoli G, Krietsch J, Weick A et al (2013) Human CD1c + dendritic cells secrete high levels of IL-12 and potently prime cytotoxic T cell responses. Blood 122:932–942
Google Scholar
Hsieh CS, Macatonia SE, Tripp CS, Wolf SF, O’Garra A, Murphy KM (1993) Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science 260:547–549
PubMed
CAS
Google Scholar
Michelin MA, Abdalla DR, Aleixo AA, Murta EF (2013) Peripheral helper lymphocytes produce interleukin 12 in cancer patients. Clin Med Insights Oncol 7:75–81
PubMed Central
PubMed
CAS
Google Scholar
Kuka M, Munitic I, Ashwell JD (2012) Identification and characterization of polyclonal alphabeta-T cells with dendritic cell properties. Nat Commun 3:1223
PubMed Central
PubMed
Google Scholar
Lee SM, Suen Y, Qian J, Knoppel E, Cairo MS (1998) The regulation and biological activity of interleukin 12. Leuk Lymphoma 29:427–438
PubMed
CAS
Google Scholar
Ling P, Gately MK, Gubler U, Stern AS, Lin P, Hollfelder K, Su C, Pan YC, Hakimi J (1995) Human IL-12 p40 homodimer binds to the IL-12 receptor but does not mediate biologic activity. J Immunol 154:116–127
PubMed
CAS
Google Scholar
Hamza T, Barnett JB, Li B (2010) Interleukin 12 a key immunoregulatory cytokine in infection applications. Int J Mol Sci 11:789–806
PubMed Central
PubMed
CAS
Google Scholar
Pistoia V, Cocco C, Airoldi I (2009) Interleukin-12 receptor beta2: from cytokine receptor to gatekeeper gene in human B-cell malignancies. J Clin Oncol 27:4809–4816
PubMed
CAS
Google Scholar
Thierfelder WE, van Deursen JM, Yamamoto K et al (1996) Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells. Nature 382:171–174
PubMed
CAS
Google Scholar
Schulz O, Edwards AD, Schito M, Aliberti J, Manickasingham S, Sher A, Reis e Sousa C (2000) CD40 triggering of heterodimeric IL-12 p70 production by dendritic cells in vivo requires a microbial priming signal. Immunity 13:453–462
PubMed
CAS
Google Scholar
Zhang Y, Ma CJ, Wang JM, Ji XJ, Wu XY, Jia ZS, Moorman JP, Yao ZQ (2011) Tim-3 negatively regulates IL-12 expression by monocytes in HCV infection. PLoS ONE 6:e19664
PubMed Central
PubMed
CAS
Google Scholar
Wesa AK, Galy A (2001) IL-1 beta induces dendritic cells to produce IL-12. Int Immunol 13:1053–1061
PubMed
CAS
Google Scholar
Kelsall BL, Stuber E, Neurath M, Strober W (1996) Interleukin-12 production by dendritic cells. The role of CD40-CD40L interactions in Th1 T-cell responses. Ann N Y Acad Sci 795:116–126
PubMed
CAS
Google Scholar
Felzmann T, Buchberger M, Lehner M, Printz D, Kircheis R, Wagner E, Gadner H, Holter W (2001) Functional maturation of dendritic cells by exposure to CD40L transgenic tumor cells, fibroblasts or keratinocytes. Cancer Lett 168:145–154
PubMed
CAS
Google Scholar
McRae BL, Semnani RT, Hayes MP, van Seventer GA (1998) Type I IFNs inhibit human dendritic cell IL-12 production and Th1 cell development. J Immunol 160:4298–4304
PubMed
CAS
Google Scholar
Bellone G, Turletti A, Artusio E, Mareschi K, Carbone A, Tibaudi D, Robecchi A, Emanuelli G, Rodeck U (1999) Tumor-associated transforming growth factor-beta and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients. Am J Pathol 155:537–547
PubMed Central
PubMed
CAS
Google Scholar
Mitsuhashi M, Liu J, Cao S, Shi X, Ma X (2004) Regulation of interleukin-12 gene expression and its anti-tumor activities by prostaglandin E2 derived from mammary carcinomas. J Leukoc Biol 76:322–332
PubMed Central
PubMed
CAS
Google Scholar
Alderton GK (2012) Immunology: TIM3 suppresses antitumour DCs. Nat Rev Cancer 12:584
PubMed
Google Scholar
Chen X, Du Y, Huang Z (2012) CD4+ CD25+ Treg derived from hepatocellular carcinoma mice inhibits tumor immunity. Immunol Lett 148:83–89
PubMed
CAS
Google Scholar
Memarian A, Nourizadeh M, Masoumi F, Tabrizi M, Emami AH, Alimoghaddam K, Hadjati J, Mirahmadian M, Jeddi-Tehrani M (2013) Upregulation of CD200 is associated with Foxp3+ regulatory T cell expansion and disease progression in acute myeloid leukemia. Tumour Biol 34:531–542
PubMed
CAS
Google Scholar
Ferretti E, Di Carlo E, Cocco C, Ribatti D, Sorrentino C, Ognio E, Montagna D, Pistoia V, Airoldi I (2010) Direct inhibition of human acute myeloid leukemia cell growth by IL-12. Immunol Lett 133:99–105
PubMed
CAS
Google Scholar
Otani T, Nakamura S, Toki M, Motoda R, Kurimoto M, Orita K (1999) Identification of IFN-gamma-producing cells in IL-12/IL-18-treated mice. Cell Immunol 198:111–119
PubMed
CAS
Google Scholar
Zeh HJ III, Hurd S, Storkus WJ, Lotze MT (1993) Interleukin-12 promotes the proliferation and cytolytic maturation of immune effectors: implications for the immunotherapy of cancer. J Immunother Emphas Tumor Immunol 14:155–161
CAS
Google Scholar
Trinchieri G, Wysocka M, D’Andrea A, Rengaraju M, Aste-Amezaga M, Kubin M, Valiante NM, Chehimi J (1992) Natural killer cell stimulatory factor (NKSF) or interleukin-12 is a key regulator of immune response and inflammation. Prog Growth Factor Res 4:355–368
PubMed
CAS
Google Scholar
Parihar R, Dierksheide J, Hu Y, Carson WE (2002) IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells. J Clin Invest 110:983–992
PubMed Central
PubMed
CAS
Google Scholar
Luedke E, Jaime-Ramirez AC, Bhave N, Roda J, Choudhary MM, Kumar B, Teknos TN, Carson WE 3rd (2012) Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines. Surgery 152:431–440
PubMed Central
PubMed
Google Scholar
Yoshimoto T, Nagai N, Ohkusu K, Ueda H, Okamura H, Nakanishi K (1998) LPS-stimulated SJL macrophages produce IL-12 and IL-18 that inhibit IgE production in vitro by induction of IFN-gamma production from CD3intIL-2R beta + T cells. J Immunol 161:1483–1492
PubMed
CAS
Google Scholar
Angiolillo AL, Sgadari C, Tosato G (1996) A role for the interferon-inducible protein 10 in inhibition of angiogenesis by interleukin-12. Ann N Y Acad Sci 795:158–167
PubMed
CAS
Google Scholar
Kerkar SP, Leonardi AJ, van Panhuys N et al (2013) Collapse of the tumor stroma is triggered by IL-12 induction of Fas. Mol Ther 21:1369–1377
PubMed
CAS
Google Scholar
Kerkar SP, Goldszmid RS, Muranski P et al (2011) IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J Clin Invest 121:4746–4757
PubMed Central
PubMed
CAS
Google Scholar
Suzuki S, Umezu Y, Saijo Y, Satoh G, Abe Y, Satoh K, Nukiwa T (1998) Exogenous recombinant human IL-12 augments MHC class I antigen expression on human cancer cells in vitro. Tohoku J Exp Med 185:223–226
PubMed
CAS
Google Scholar
Golab J, Zagozdzon R (1999) Antitumor effects of interleukin-12 in pre-clinical and early clinical studies (review). Int J Mol Med 3:537–544
PubMed
CAS
Google Scholar
Del Vecchio M, Bajetta E, Canova S, Lotze MT, Wesa A, Parmiani G, Anichini A (2007) Interleukin-12: biological properties and clinical application. Clin Cancer Res 13:4677–4685
PubMed
Google Scholar
Yang ZZ, Grote DM, Ziesmer SC, Niki T, Hirashima M, Novak AJ, Witzig TE, Ansell SM (2012) IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma. J Clin Invest 122:1271–1282
PubMed Central
PubMed
CAS
Google Scholar
Wang JM, Ma CJ, Li GY et al (2013) Tim-3 alters the balance of IL-12/IL-23 and drives TH17 cells: role in hepatitis B vaccine failure during hepatitis C infection. Vaccine 31:2238–2245
PubMed
CAS
Google Scholar
Voest EE, Kenyon BM, O’Reilly MS, Truitt G, D’Amato RJ, Folkman J (1995) Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 87:581–586
PubMed
CAS
Google Scholar
Li S, Xia X, Mellieon FM, Liu J, Steele S (2004) Candidate genes associated with tumor regression mediated by intratumoral IL-12 electroporation gene therapy. Mol Ther 9:347–354
PubMed
CAS
Google Scholar
Zhu XD, Sun HC, Xu HX et al (2013) Antiangiogenic therapy promoted metastasis of hepatocellular carcinoma by suppressing host-derived interleukin-12b in mouse models. Angiogenesis 16:809–820
Google Scholar
Fogler WE, Volker K, Watanabe M, Wigginton JM, Roessler P, Brunda MJ, Ortaldo JR, Wiltrout RH (1998) Recruitment of hepatic NK cells by IL-12 is dependent on IFN-gamma and VCAM-1 and is rapidly down-regulated by a mechanism involving T cells and expression of Fas. J Immunol 161:6014–6021
PubMed
CAS
Google Scholar
Weiss JM, Subleski JJ, Wigginton JM, Wiltrout RH (2007) Immunotherapy of cancer by IL-12-based cytokine combinations. Expert Opin Biol Ther 7:1705–1721
PubMed Central
PubMed
CAS
Google Scholar
Lasek W, Feleszko W, Golab J, Stoklosa T, Marczak M, Dabrowska A, Malejczyk M, Jakobisiak M (1997) Antitumor effects of the combination immunotherapy with interleukin-12 and tumor necrosis factor alpha in mice. Cancer Immunol Immunother 45:100–108
PubMed
CAS
Google Scholar
Zagozdzon R, Stoklosa T, Golab J, Giermasz A, Dabrowska A, Lasek W, Jakobisiak M (1997) Augmented antitumor effects of combination therapy with interleukin-12, cisplatin, and tumor necrosis factor-alpha in a murine melanoma model. Anticancer Res 17:4493–4498
PubMed
CAS
Google Scholar
Pappo I, Tahara H, Robbins PD, Gately MK, Wolf SF, Barnea A, Lotze MT (1995) Administration of systemic or local interleukin-2 enhances the anti-tumor effects of interleukin-12 gene therapy. J Surg Res 58:218–226
PubMed
CAS
Google Scholar
Rossi AR, Pericle F, Rashleigh S, Janiec J, Djeu JY (1994) Lysis of neuroblastoma cell lines by human natural killer cells activated by interleukin-2 and interleukin-12. Blood 83:1323–1328
PubMed
CAS
Google Scholar
Lasek W, Basak G, Switaj T et al (2004) Complete tumour regressions induced by vaccination with IL-12 gene-transduced tumour cells in combination with IL-15 in a melanoma model in mice. Cancer Immunol Immunother 53:363–372
PubMed
CAS
Google Scholar
Ni J, Miller M, Stojanovic A, Garbi N, Cerwenka A (2012) Sustained effector function of IL-12/15/18-preactivated NK cells against established tumors. J Exp Med 209:2351–2365
PubMed Central
PubMed
CAS
Google Scholar
Golab J, Zagozdzon R, Stoklosal T, Kaminski R, Kozar K, Jakobisiak M (2000) Direct stimulation of macrophages by IL-12 and IL-18—a bridge too far? Immunol Lett 72:153–157
PubMed
CAS
Google Scholar
Golab J, Stoklosa T, Zagozdzon R et al (1998) Granulocyte–macrophage colony-stimulating factor potentiates antitumor activity of interleukin-12 in melanoma model in mice. Tumour Biol 19:77–87
PubMed
CAS
Google Scholar
Golab J, Stoklosa T, Zagozdzon R et al (1998) G-CSF prevents the suppression of bone marrow hematopoiesis induced by IL-12 and augments its antitumor activity in a melanoma model in mice. Ann Oncol 9:63–69
PubMed
CAS
Google Scholar
Golab J, Zagozdzon R, Stoklosa T, Jakobisiak M, Pojda Z, Machaj E (1998) Erythropoietin prevents the development of interleukin-12-induced anemia and thrombocytopenia but does not decrease its antitumor activity in mice. Blood 91:4387–4388
PubMed
CAS
Google Scholar
Basile LA, Gallaher TK, Shibata D, Miller JD, Douer D (2008) Multilineage hematopoietic recovery with concomitant antitumor effects using low dose Interleukin-12 in myelosuppressed tumor-bearing mice. J Transl Med 6:26
PubMed Central
PubMed
Google Scholar
Brunda MJ, Luistro L, Warrier RR, Wright RB, Hubbard BR, Murphy M, Wolf SF, Gately MK (1993) Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 178:1223–1230
PubMed
CAS
Google Scholar
Teicher BA, Ara G, Menon K, Schaub RG (1996) In vivo studies with interleukin-12 alone and in combination with monocyte colony-stimulating factor and/or fractionated radiation treatment. Int J Cancer 65:80–84
PubMed
CAS
Google Scholar
Kozar K, Kaminski R, Switaj T et al (2003) Interleukin 12-based immunotherapy improves the antitumor effectiveness of a low-dose 5-Aza-2′-deoxycitidine treatment in L1210 leukemia and B16F10 melanoma models in mice. Clin Cancer Res 9:3124–3133
PubMed
CAS
Google Scholar
Cao L, Zeng Q, Xu C, Shi S, Zhang Z, Sun X (2013) Enhanced antitumor response mediated by the codelivery of paclitaxel and adenoviral vector expressing IL-12. Mol Pharm 10:1804–1814
PubMed
CAS
Google Scholar
Teicher BA, Ara G, Buxton D, Leonard J, Schaub RG (1997) Optimal scheduling of interleukin 12 and chemotherapy in the murine MB-49 bladder carcinoma and B16 melanoma. Clin Cancer Res 3:1661–1667
PubMed
CAS
Google Scholar
Zagozdzon R, Golab J, Mucha K, Foroncewicz B, Jakobisiak M (1999) Potentiation of antitumor effects of IL-12 in combination with paclitaxel in murine melanoma model in vivo. Int J Mol Med 4:645–648
PubMed
CAS
Google Scholar
Golab J, Zagozdzon R, Kaminski R et al (2001) Potentiated antitumor effectiveness of combined chemo-immunotherapy with interleukin-12 and 5-fluorouracil of L1210 leukemia in vivo. Leukemia 15:613–620
CAS
Google Scholar
Xia X, Li X, Feng G, Zheng C, Liang H, Zhou G (2013) Intra-arterial interleukin-12 gene delivery combined with chemoembolization: anti-tumor effect in a rabbit hepatocellular carcinoma (HCC) model. Acta Radiol
Golab J, Zagozdzon R, Kozar K, Kaminski R, Giermasz A, Stoklosa T, Lasek W, Jakobisiak M (2000) Potentiated anti-tumor effectiveness of combined therapy with interleukin-12 and mitoxantrone of L1210 leukemia in vivo. Oncol Rep 7:177–181
PubMed
CAS
Google Scholar
Zagozdzon R, Golab J, Stoklosa T, Giermasz A, Nowicka D, Feleszko W, Lasek W, Jakobisiak M (1998) Effective chemo-immunotherapy of L1210 leukemia in vivo using interleukin-12 combined with doxorubicin but not with cyclophosphamide, paclitaxel or cisplatin. Int J Cancer 77:720–727
PubMed
CAS
Google Scholar
Wigginton JM, Park JW, Gruys ME et al (2001) Complete regression of established spontaneous mammary carcinoma and the therapeutic prevention of genetically programmed neoplastic transition by IL-12/pulse IL-2: induction of local T cell infiltration, Fas/Fas ligand gene expression, and mammary epithelial apoptosis. J Immunol 166:1156–1168
PubMed
CAS
Google Scholar
Osaki T, Hashimoto W, Gambotto A, Okamura H, Robbins PD, Kurimoto M, Lotze MT, Tahara H (1999) Potent antitumor effects mediated by local expression of the mature form of the interferon-gamma inducing factor, interleukin-18 (IL-18). Gene Ther 6:808–815
PubMed
CAS
Google Scholar
Dabrowska A, Giermasz A, Golab J, Jakobisiak M (2001) Potentiated antitumor effects of interleukin 12 and interferon alpha against B16F10 melanoma in mice. Neoplasma 48:358–361
PubMed
CAS
Google Scholar
Lesinski GBB, Zimmerer J, Crespin T, Hu Y, Abood G, Carson WE III (2004) IL-12 pretreatments enhance IFN-alpha-induced Janus kinase-STAT signaling and potentiate the antitumor effects of IFN-alpha in a murine model of malignant melanoma. J Immunol 172:7368–7376
PubMed
CAS
Google Scholar
Yao L, Pike SE, Setsuda J, Parekh J, Gupta G, Raffeld M, Jaffe ES, Tosato G (2000) Effective targeting of tumor vasculature by the angiogenesis inhibitors vasostatin and interleukin-12. Blood 96:1900–1905
PubMed
CAS
Google Scholar
Teicher BA, Ara G, Buxton D, Leonard J, Schaub RG (1998) Optimal scheduling of interleukin-12 and fractionated radiation therapy in the murine Lewis lung carcinoma. Radiat Oncol Investig 6:71–80
PubMed
CAS
Google Scholar
Helms MW, Prescher JA, Cao YA, Schaffert S, Contag CH (2010) IL-12 enhances efficacy and shortens enrichment time in cytokine-induced killer cell immunotherapy. Cancer Immunol Immunother 59:1325–1334
PubMed
CAS
Google Scholar
Zapala L, Wolny R, Wachowska M, Jakobisiak M, Lasek W (2013) Synergistic antitumor effect of JAWSII dendritic cells and interleukin 12 in a melanoma mouse model. Oncol Rep 29:1208–1214
PubMed
CAS
Google Scholar
Tatsumi T, Takehara T, Kanto T et al (2001) Administration of interleukin-12 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines in mouse hepatocellular carcinoma. Cancer Res 61:7563–7567
PubMed
CAS
Google Scholar
Vagliani M, Rodolfo M, Cavallo F, Parenza M, Melani C, Parmiani G, Forni G, Colombo MP (1996) Interleukin 12 potentiates the curative effect of a vaccine based on interleukin 2-transduced tumor cells. Cancer Res 56:467–470
PubMed
CAS
Google Scholar
Kikuchi T, Joki T, Saitoh S, Hata Y, Abe T, Kato N, Kobayashi A, Miyazaki T, Ohno T (1999) Anti-tumor activity of interleukin-2-producing tumor cells and recombinant interleukin 12 against mouse glioma cells located in the central nervous system. Int J Cancer 80:425–430
PubMed
CAS
Google Scholar
Noguchi Y, Richards EC, Chen YT, Old LJ (1995) Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma. Proc Natl Acad Sci USA 92:2219–2223
PubMed Central
PubMed
CAS
Google Scholar
Ramakrishnan R, Gabrilovich DI (2011) Mechanism of synergistic effect of chemotherapy and immunotherapy of cancer. Cancer Immunol Immunother 60:419–423
PubMed
CAS
Google Scholar
Nars MS, Kaneno R (2013) Immunomodulatory effects of low dose chemotherapy and perspectives of its combination with immunotherapy. Int J Cancer 132:2471–2478
PubMed
CAS
Google Scholar
Shurin GV, Tourkova IL, Kaneno R, Shurin MR (2009) Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism. J Immunol 183:137–144
PubMed
CAS
Google Scholar
Wennerberg E, Sarhan D, Carlsten M, Kaminskyy VO, D’Arcy P, Zhivotovsky B, Childs R, Lundqvist A (2013) Doxorubicin sensitizes human tumor cells to NK cell- and T-cell-mediated killing by augmented TRAIL receptor signaling. Int J Cancer 133:1643–1652
PubMed
CAS
Google Scholar
Apetoh L, Ghiringhelli F, Tesniere A et al (2007) Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 13:1050–1059
PubMed
CAS
Google Scholar
Basile LA, Ellefson D, Gluzman-Poltorak Z et al (2012) HemaMax, a recombinant human interleukin-12, is a potent mitigator of acute radiation injury in mice and non-human primates. PLoS ONE 7:e30434
PubMed Central
PubMed
CAS
Google Scholar
Mori K, Fujimoto-Ouchi K, Ishikawa T, Sekiguchi F, Ishitsuka H, Tanaka Y (1996) Murine interleukin-12 prevents the development of cancer cachexia in a murine model. Int J Cancer 67:849–855
PubMed
CAS
Google Scholar
Gately MK, Gubler U, Brunda MJ, Nadeau RR, Anderson TD, Lipman JM, Sarmiento U (1994) Interleukin-12: a cytokine with therapeutic potential in oncology and infectious diseases. Ther Immunol 1:187–196
PubMed
CAS
Google Scholar
Sarmiento UM, Riley JH, Knaack PA, Lipman JM, Becker JM, Gately MK, Chizzonite R, Anderson TD (1994) Biologic effects of recombinant human interleukin-12 in squirrel monkeys (Sciureus saimiri). Lab Invest 71:862–873
PubMed
CAS
Google Scholar
Eng VM, Car BD, Schnyder B, Lorenz M, Lugli S, Aguet M, Anderson TD, Ryffel B, Quesniaux VF (1995) The stimulatory effects of interleukin (IL)-12 on hematopoiesis are antagonized by IL-12-induced interferon gamma in vivo. J Exp Med 181:1893–1898
PubMed
CAS
Google Scholar
Quetglas JI, Ruiz-Guillen M, Aranda A, Casales E, Bezunartea J, Smerdou C (2010) Alphavirus vectors for cancer therapy. Virus Res 153:179–196
PubMed
CAS
Google Scholar
Tahara H, Zitvogel L, Storkus WJ, Zeh HJ III, McKinney TG, Schreiber RD, Gubler U, Robbins PD, Lotze MT (1995) Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J Immunol 154:6466–6474
PubMed
CAS
Google Scholar
Quetglas JI, Rodriguez-Madoz JR, Bezunartea J et al (2013) Eradication of liver-implanted tumors by Semliki Forest virus expressing IL-12 requires efficient long-term immune responses. J Immunol 190:2994–3004
PubMed
CAS
Google Scholar
Fewell JG, Matar MM, Rice JS, Brunhoeber E, Slobodkin G, Pence C, Worker M, Lewis DH, Anwer K (2009) Treatment of disseminated ovarian cancer using nonviral interleukin-12 gene therapy delivered intraperitoneally. J Gene Med 11:718–728
PubMed
CAS
Google Scholar
Lucas ML, Heller L, Coppola D, Heller R (2002) IL-12 plasmid delivery by in vivo electroporation for the successful treatment of established subcutaneous B16.F10 melanoma. Mol Ther 5:668–675
PubMed
CAS
Google Scholar
Mendiratta SK, Quezada A, Matar M, Wang J, Hebel HL, Long S, Nordstrom JL, Pericle F (1999) Intratumoral delivery of IL-12 gene by polyvinyl polymeric vector system to murine renal and colon carcinoma results in potent antitumor immunity. Gene Ther 6:833–839
PubMed
CAS
Google Scholar
Heinzerling LM, Feige K, Rieder S, Akens MK, Dummer R, Stranzinger G, Moelling K (2001) Tumor regression induced by intratumoral injection of DNA coding for human interleukin 12 into melanoma metastases in gray horses. J Mol Med (Berl) 78:692–702
CAS
Google Scholar
Caruso M, Pham-Nguyen K, Kwong YL, Xu B, Kosai KI, Finegold M, Woo SL, Chen SH (1996) Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma. Proc Natl Acad Sci USA 93:11302–11306
PubMed Central
PubMed
CAS
Google Scholar
Nasu Y, Bangma CH, Hull GW et al (1999) Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic model. Gene Ther 6:338–349
PubMed
CAS
Google Scholar
Zitvogel L, Tahara H, Robbins PD, Storkus WJ, Clarke MR, Nalesnik MA, Lotze MT (1995) Cancer immunotherapy of established tumors with IL-12. Effective delivery by genetically engineered fibroblasts. J Immunol 155:1393–1403
PubMed
CAS
Google Scholar
Song K, Chang Y, Prud’homme GJ (2000) IL-12 plasmid-enhanced DNA vaccination against carcinoembryonic antigen (CEA) studied in immune-gene knockout mice. Gene Ther 7:1527–1535
PubMed
CAS
Google Scholar
Rodolfo M, Zilocchi C, Melani C, Cappetti B, Arioli I, Parmiani G, Colombo MP (1996) Immunotherapy of experimental metastases by vaccination with interleukin gene-transduced adenocarcinoma cells sharing tumor-associated antigens. Comparison between IL-12 and IL-2 gene-transduced tumor cell vaccines. J Immunol 157:5536–5542
PubMed
CAS
Google Scholar
Dunussi-Joannopoulos K, Leonard JP (2001) Interleukin-12 gene therapy vaccines: directing the immune system against minimal residual leukemia. Leuk Lymphoma 41:483–492
PubMed
CAS
Google Scholar
Huang C, Ramakrishnan R, Trkulja M, Ren X, Gabrilovich DI (2012) Therapeutic effect of intratumoral administration of DCs with conditional expression of combination of different cytokines. Cancer Immunol Immunother 61:573–579
PubMed
CAS
Google Scholar
Zitvogel L, Couderc B, Mayordomo JI, Robbins PD, Lotze MT, Storkus WJ (1996) IL-12-engineered dendritic cells serve as effective tumor vaccine adjuvants in vivo. Ann N Y Acad Sci 795:284–293
PubMed
CAS
Google Scholar
Chen Y, Emtage P, Zhu Q, Foley R, Muller W, Hitt M, Gauldie J, Wan Y (2001) Induction of ErbB-2/neu-specific protective and therapeutic antitumor immunity using genetically modified dendritic cells: enhanced efficacy by cotransduction of gene encoding IL-12. Gene Ther 8:316–323
PubMed
CAS
Google Scholar
Pegram HJ, Lee JC, Hayman EG, Imperato GH, Tedder TF, Sadelain M, Brentjens RJ (2012) Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood 119:4133–4141
PubMed Central
PubMed
CAS
Google Scholar
Cody JJ, Scaturro P, Cantor AB, Yancey Gillespie G, Parker JN, Markert JM (2012) Preclinical evaluation of oncolytic deltagamma(1)34.5 herpes simplex virus expressing interleukin-12 for therapy of breast cancer brain metastases. Int J Breast Cancer 2012:628697
Charoensit P, Kawakami S, Higuchi Y, Yamashita F, Hashida M (2010) Enhanced growth inhibition of metastatic lung tumors by intravenous injection of ATRA-cationic liposome/IL-12 pDNA complexes in mice. Cancer Gene Ther 17:512–522
PubMed
CAS
Google Scholar
Wilczynska U, Kucharska A, Szary J, Szala S (2001) Combined delivery of an antiangiogenic protein (angiostatin) and an immunomodulatory gene (interleukin-12) in the treatment of murine cancer. Acta Biochim Pol 48:1077–1084
PubMed
CAS
Google Scholar
Addison CL, Bramson JL, Hitt MM, Muller WJ, Gauldie J, Graham FL (1998) Intratumoral coinjection of adenoviral vectors expressing IL-2 and IL-12 results in enhanced frequency of regression of injected and untreated distal tumors. Gene Ther 5:1400–1409
PubMed
CAS
Google Scholar
Coughlin CM, Salhany KE, Wysocka M et al (1998) Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. J Clin Invest 101:1441–1452
PubMed Central
PubMed
CAS
Google Scholar
Zhu S, Lee DA, Li S (2010) IL-12 and IL-27 sequential gene therapy via intramuscular electroporation delivery for eliminating distal aggressive tumors. J Immunol 184:2348–2354
PubMed Central
PubMed
CAS
Google Scholar
Palmer K, Hitt M, Emtage PC, Gyorffy S, Gauldie J (2001) Combined CXC chemokine and interleukin-12 gene transfer enhances antitumor immunity. Gene Ther 8:282–290
PubMed
CAS
Google Scholar
Emtage PC, Wan Y, Hitt M, Graham FL, Muller WJ, Zlotnik A, Gauldie J (1999) Adenoviral vectors expressing lymphotactin and interleukin 2 or lymphotactin and interleukin 12 synergize to facilitate tumor regression in murine breast cancer models. Hum Gene Ther 10:697–709
PubMed
CAS
Google Scholar
Putzer BM, Hitt M, Muller WJ, Emtage P, Gauldie J, Graham FL (1997) Interleukin 12 and B7-1 costimulatory molecule expressed by an adenovirus vector act synergistically to facilitate tumor regression. Proc Natl Acad Sci USA 94:10889–10894
PubMed Central
PubMed
CAS
Google Scholar
Quetglas JI, Dubrot J, Bezunartea J, Sanmamed MF, Hervas-Stubbs S, Smerdou C, Melero I (2012) Immunotherapeutic synergy between anti-CD137 mAb and intratumoral administration of a cytopathic Semliki Forest virus encoding IL-12. Mol Ther 20:1664–1675
PubMed Central
PubMed
CAS
Google Scholar
Martinet O, Ermekova V, Qiao JQ, Sauter B, Mandeli J, Chen L, Chen SH (2000) Immunomodulatory gene therapy with interleukin 12 and 4-1BB ligand: long-term remission of liver metastases in a mouse model. J Natl Cancer Inst 92:931–936
PubMed
CAS
Google Scholar
Switaj T, Jalili A, Jakubowska AB et al (2004) CpG immunostimulatory oligodeoxynucleotide 1826 enhances antitumor effect of interleukin 12 gene-modified tumor vaccine in a melanoma model in mice. Clin Cancer Res 10:4165–4175
PubMed
CAS
Google Scholar
Lamont AG, Adorini L (1996) IL-12: a key cytokine in immune regulation. Immunol Today 17:214–217
PubMed
CAS
Google Scholar
Jenks S (1996) After initial setback, IL-12 regaining popularity. J Natl Cancer Inst 88:576–577
PubMed
CAS
Google Scholar
Leonard JP, Sherman ML, Fisher GL et al (1997) Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood 90:2541–2548
PubMed
CAS
Google Scholar
Cohen J (1995) IL-12 deaths: explanation and a puzzle. Science 270:908
PubMed
CAS
Google Scholar
Atkins MB, Robertson MJ, Gordon M et al (1997) Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res 3:409–417
PubMed
CAS
Google Scholar
Robertson MJ, Cameron C, Atkins MB, Gordon MS, Lotze MT, Sherman ML, Ritz J (1999) Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer. Clin Cancer Res 5:9–16
PubMed
CAS
Google Scholar
Gollob JA, Mier JW, Veenstra K, McDermott DF, Clancy D, Clancy M, Atkins MB (2000) Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response. Clin Cancer Res 6:1678–1692
PubMed
CAS
Google Scholar
Bajetta E, Del Vecchio M, Mortarini R et al (1998) Pilot study of subcutaneous recombinant human interleukin 12 in metastatic melanoma. Clin Cancer Res 4:75–85
PubMed
CAS
Google Scholar
Motzer RJ, Rakhit A, Schwartz LH, Olencki T, Malone TM, Sandstrom K, Nadeau R, Parmar H, Bukowski R (1998) Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma. Clin Cancer Res 4:1183–1191
PubMed
CAS
Google Scholar
Lenzi R, Rosenblum M, Verschraegen C et al (2002) Phase I study of intraperitoneal recombinant human interleukin 12 in patients with Mullerian carcinoma, gastrointestinal primary malignancies, and mesothelioma. Clin Cancer Res 8:3686–3695
PubMed
CAS
Google Scholar
Wadler S, Levy D, Frederickson HL et al (2004) A phase II trial of interleukin-12 in patients with advanced cervical cancer: clinical and immunologic correlates. Eastern Cooperative Oncology Group study E1E96. Gynecol Oncol 92:957–964
PubMed
CAS
Google Scholar
Haicheur N, Escudier B, Dorval T et al (2000) Cytokines and soluble cytokine receptor induction after IL-12 administration in cancer patients. Clin Exp Immunol 119:28–37
PubMed Central
PubMed
CAS
Google Scholar
Portielje JE, Kruit WH, Schuler M et al (1999) Phase I study of subcutaneously administered recombinant human interleukin 12 in patients with advanced renal cell cancer. Clin Cancer Res 5:3983–3989
PubMed
CAS
Google Scholar
Portielje JE, Lamers CH, Kruit WH, Sparreboom A, Bolhuis RL, Stoter G, Huber C, Gratama JW (2003) Repeated administrations of interleukin (IL)-12 are associated with persistently elevated plasma levels of IL-10 and declining IFN-gamma, tumor necrosis factor-alpha, IL-6, and IL-8 responses. Clin Cancer Res 9:76–83
PubMed
CAS
Google Scholar
Bekaii-Saab TS, Roda JM, Guenterberg KD et al (2009) A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies. Mol Cancer Ther 8:2983–2991
PubMed Central
PubMed
CAS
Google Scholar
Gabrilovich DI, Ostrand-Rosenberg S, Bronte V (2012) Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 12:253–268
PubMed Central
PubMed
CAS
Google Scholar
Becker JC, Andersen MH, Schrama D, Thor Straten P (2013) Immune-suppressive properties of the tumor microenvironment. Cancer Immunol Immunother 62:1137–1148
PubMed
CAS
Google Scholar
Parihar R, Nadella P, Lewis A et al (2004) A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon gamma production in a subset of patients. Clin Cancer Res 10:5027–5037
PubMed
CAS
Google Scholar
Ansell SM, Geyer SM, Maurer MJ et al (2006) Randomized phase II study of interleukin-12 in combination with rituximab in previously treated non-Hodgkin’s lymphoma patients. Clin Cancer Res 12:6056–6063
PubMed
CAS
Google Scholar
Hamid O, Solomon JC, Scotland R, Garcia M, Sian S, Ye W, Groshen SL, Weber JS (2007) Alum with interleukin-12 augments immunity to a melanoma peptide vaccine: correlation with time to relapse in patients with resected high-risk disease. Clin Cancer Res 13:215–222
PubMed
CAS
Google Scholar
Lee P, Wang F, Kuniyoshi J et al (2001) Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma. J Clin Oncol 19:3836–3847
PubMed
CAS
Google Scholar
Hansson L, Abdalla AO, Moshfegh A, Choudhury A, Rabbani H, Nilsson B, Osterborg A, Mellstedt H (2007) Long-term idiotype vaccination combined with interleukin-12 (IL-12), or IL-12 and granulocyte macrophage colony-stimulating factor, in early-stage multiple myeloma patients. Clin Cancer Res 13:1503–1510
PubMed
CAS
Google Scholar
Peterson AC, Harlin H, Gajewski TF (2003) Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma. J Clin Oncol 21:2342–2348
PubMed
CAS
Google Scholar
Little RF, Aleman K, Kumar P et al (2007) Phase 2 study of pegylated liposomal doxorubicin in combination with interleukin-12 for AIDS-related Kaposi sarcoma. Blood 110:4165–4171
PubMed Central
PubMed
CAS
Google Scholar
Gollob JA, Veenstra KG, Parker RA, Mier JW, McDermott DF, Clancy D, Tutin L, Koon H, Atkins MB (2003) Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma. J Clin Oncol 21:2564–2573
PubMed
Google Scholar
Eisenbeis CF, Lesinski GB, Anghelina M et al (2005) Phase I study of the sequential combination of interleukin-12 and interferon alfa-2b in advanced cancer: evidence for modulation of interferon signaling pathways by interleukin-12. J Clin Oncol 23:8835–8844
PubMed
CAS
Google Scholar
Alatrash G, Hutson TE, Molto L et al (2004) Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma. J Clin Oncol 22:2891–2900
PubMed
CAS
Google Scholar
Kang WK, Park C, Yoon HL et al (2001) Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: outcome of a phase I study. Hum Gene Ther 12:671–684
PubMed
CAS
Google Scholar
Sangro B, Mazzolini G, Ruiz J et al (2004) Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. J Clin Oncol 22:1389–1397
PubMed
CAS
Google Scholar
Mazzolini G, Prieto J, Melero I (2003) Gene therapy of cancer with interleukin-12. Curr Pharm Des 9:1981–1991
PubMed
CAS
Google Scholar
Sun Y, Jurgovsky K, Moller P, Alijagic S, Dorbic T, Georgieva J, Wittig B, Schadendorf D (1998) Vaccination with IL-12 gene-modified autologous melanoma cells: preclinical results and a first clinical phase I study. Gene Ther 5:481–490
PubMed
CAS
Google Scholar
Triozzi PL, Strong TV, Bucy RP, Allen KO, Carlisle RR, Moore SE, Lobuglio AF, Conry RM (2005) Intratumoral administration of a recombinant canarypox virus expressing interleukin 12 in patients with metastatic melanoma. Hum Gene Ther 16:91–100
PubMed
CAS
Google Scholar
Triozzi PL, Allen KO, Carlisle RR, Craig M, LoBuglio AF, Conry RM (2005) Phase I study of the intratumoral administration of recombinant canarypox viruses expressing B7.1 and interleukin 12 in patients with metastatic melanoma. Clin Cancer Res 11:4168–4175
PubMed
CAS
Google Scholar
Rook AH, Kubin M, Cassin M et al (1995) IL-12 reverses cytokine and immune abnormalities in Sezary syndrome. J Immunol 154:1491–1498
PubMed
CAS
Google Scholar
Rook AH, Wood GS, Yoo EK et al (1999) Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses. Blood 94:902–908
PubMed
CAS
Google Scholar
Duvic M, Sherman ML, Wood GS et al (2006) A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoides. J Am Acad Dermatol 55:807–813
PubMed
Google Scholar
Younes A, Pro B, Robertson MJ et al (2004) Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkin’s lymphoma and Hodgkin’s disease. Clin Cancer Res 10:5432–5438
PubMed
CAS
Google Scholar
Ansell SM, Witzig TE, Kurtin PJ et al (2002) Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma. Blood 99:67–74
PubMed
CAS
Google Scholar
Lunning MA, Vose JM (2012) Management of indolent lymphoma: where are we now and where are we going. Blood Rev 26:279–288
PubMed Central
PubMed
Google Scholar
Little RF, Pluda JM, Wyvill KM, Rodriguez-Chavez IR, Tosato G, Catanzaro AT, Steinberg SM, Yarchoan R (2006) Activity of subcutaneous interleukin-12 in AIDS-related Kaposi sarcoma. Blood 107:4650–4657
PubMed Central
PubMed
CAS
Google Scholar
Motzer RJ, Rakhit A, Thompson JA, Nemunaitis J, Murphy BA, Ellerhorst J, Schwartz LH, Berg WJ, Bukowski RM (2001) Randomized multicenter phase II trial of subcutaneous recombinant human interleukin-12 versus interferon-alpha 2a for patients with advanced renal cell carcinoma. J Interferon Cytokine Res 21:257–263
PubMed
CAS
Google Scholar
Fransen MF, Arens R, Melief CJ (2013) Local targets for immune therapy to cancer: tumor draining lymph nodes and tumor microenvironment. Int J Cancer 132:1971–1976
PubMed
CAS
Google Scholar
Colombo MP, Vagliani M, Spreafico F, Parenza M, Chiodoni C, Melani C, Stoppacciaro A (1996) Amount of interleukin 12 available at the tumor site is critical for tumor regression. Cancer Res 56:2531–2534
PubMed
CAS
Google Scholar
Lenzi R, Edwards R, June C, Seiden MV, Garcia ME, Rosenblum M, Freedman RS (2007) Phase II study of intraperitoneal recombinant interleukin-12 (rhIL-12) in patients with peritoneal carcinomatosis (residual disease <1 cm) associated with ovarian cancer or primary peritoneal carcinoma. J Transl Med 5:66
PubMed Central
PubMed
Google Scholar
Anwer K, Barnes MN, Fewell J, Lewis DH, Alvarez RD (2010) Phase-I clinical trial of IL-12 plasmid/lipopolymer complexes for the treatment of recurrent ovarian cancer. Gene Ther 17:360–369
PubMed
CAS
Google Scholar
Anwer K, Kelly FJ, Chu C, Fewell JG, Lewis D, Alvarez RD (2013) Phase I trial of a formulated IL-12 plasmid in combination with carboplatin and docetaxel chemotherapy in the treatment of platinum-sensitive recurrent ovarian cancer. Gynecol Oncol 131:169–173
Google Scholar
Heinzerling L, Burg G, Dummer R, Maier T, Oberholzer PA, Schultz J, Elzaouk L, Pavlovic J, Moelling K (2005) Intratumoral injection of DNA encoding human interleukin 12 into patients with metastatic melanoma: clinical efficacy. Hum Gene Ther 16:35–48
PubMed
CAS
Google Scholar
Mahvi DM, Henry MB, Albertini MR, Weber S, Meredith K, Schalch H, Rakhmilevich A, Hank J, Sondel P (2007) Intratumoral injection of IL-12 plasmid DNA—results of a phase I/IB clinical trial. Cancer Gene Ther 14:717–723
PubMed
CAS
Google Scholar
Daud AI, DeConti RC, Andrews S et al (2008) Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol 26:5896–5903
PubMed Central
PubMed
CAS
Google Scholar
Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME (2008) Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 8:299–308
PubMed Central
PubMed
CAS
Google Scholar
Restifo NP, Dudley ME, Rosenberg SA (2012) Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 12:269–281
PubMed
CAS
Google Scholar
Dudley ME, Gross CA, Somerville RP et al (2013) Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma. J Clin Oncol 31:2152–2159
PubMed
CAS
Google Scholar
Linette GP, Hamid O, Whitman ED et al (2013) A phase I open-label study of Ad-RTS-hIL-12, an adenoviral vector engineered to express hIL-12 under the control of an oral activator ligand, in subjects with unrespectable stage III/IV melanoma. J Clin Oncol 31(15) suppl., 2013 ASCO Annual Meeting Abstracts, abstr. No. 3022
Avigan D, Rosenblatt J, Kufe D (2012) Dendritic/tumor fusion cells as cancer vaccines. Semin Oncol 39:287–295
PubMed
CAS
Google Scholar
Kikuchi T, Akasaki Y, Irie M, Homma S, Abe T, Ohno T (2001) Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol Immunother 50:337–344
PubMed
CAS
Google Scholar
Avigan DE, Vasir B, George DJ et al (2007) Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. J Immunother 30:749–761
PubMed
Google Scholar
Rosenblatt J, Vasir B, Uhl L et al (2011) Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma. Blood 117:393–402
PubMed Central
PubMed
CAS
Google Scholar
Rosenblatt J, Avivi I, Vasir B et al (2013) Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients. Clin Cancer Res 19:3640–3648
PubMed
CAS
Google Scholar
Gong J, Koido S, Chen D, Tanaka Y, Huang L, Avigan D, Anderson K, Ohno T, Kufe D (2002) Immunization against murine multiple myeloma with fusions of dendritic and plasmacytoma cells is potentiated by interleukin 12. Blood 99:2512–2517
PubMed
CAS
Google Scholar
Tan C, Reddy V, Dannull J, Ding E, Nair SK, Tyler DS, Pruitt SK, Lee WT (2013) Impact of anti-CD25 monoclonal antibody on dendritic cell-tumor fusion vaccine efficacy in a murine melanoma model. J Transl Med 11:148
PubMed Central
PubMed
CAS
Google Scholar
Kikuchi T, Akasaki Y, Abe T, Fukuda T, Saotome H, Ryan JL, Kufe DW, Ohno T (2004) Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12. J Immunother 27:452–459
PubMed
CAS
Google Scholar
Homma S, Sagawa Y, Ito M, Ohno T, Toda G (2006) Cancer immunotherapy using dendritic/tumour-fusion vaccine induces elevation of serum anti-nuclear antibody with better clinical responses. Clin Exp Immunol 144:41–47
PubMed Central
PubMed
CAS
Google Scholar
Frohlich MW (2012) Sipuleucel-T for the treatment of advanced prostate cancer. Semin Oncol 39:245–252
PubMed
CAS
Google Scholar
Felzmann T, Buchroithner J, Marosi C et al (2013) First interim analysis of a randomized study to evaluate safety and efficacy of individualized dendritic cell-based cancer immune therapy for glioblastoma multiforme. In: Proceedings of the 104th annual meeting of the american association for cancer research (AACR 2013), Abstr. No. 4658
Pasche N, Neri D (2012) Immunocytokines: a novel class of potent armed antibodies. Drug Discov Today 17:583–590
PubMed
CAS
Google Scholar
Rudman SM, Jameson MB, McKeage MJ, Savage P, Jodrell DI, Harries M, Acton G, Erlandsson F, Spicer JF (2011) A phase 1 study of AS1409, a novel antibody-cytokine fusion protein, in patients with malignant melanoma or renal cell carcinoma. Clin Cancer Res 17:1998–2005
PubMed Central
PubMed
CAS
Google Scholar
Gajewski TF, Fallarino F, Ashikari A, Sherman M (2001) Immunization of HLA-A2+ melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12. Clin Cancer Res 7:895s–901s
PubMed
CAS
Google Scholar
Chmielewski M, Abken H (2012) CAR T cells transform to trucks: chimeric antigen receptor-redirected T cells engineered to deliver inducible IL-12 modulate the tumour stroma to combat cancer. Cancer Immunol Immunother 61:1269–1277
PubMed
CAS
Google Scholar
Grupp SA, Kalos M, Barrett D et al (2013) Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 368:1509–1518
PubMed
CAS
Google Scholar
Porter DL, Levine BL, Kalos M, Bagg A, June CH (2011) Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365:725–733
PubMed Central
PubMed
CAS
Google Scholar
Yuzhalin AE, Kutikhin AG (2012) Interleukin-12: clinical usage and molecular markers of cancer susceptibility. Growth Factors 30:176–191
PubMed
CAS
Google Scholar
Lippitz BE (2013) Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol 14:e218–e228
PubMed
CAS
Google Scholar